The session will also give PK-PD data. This data will allow them to use for dose optimization - so the next trial may be p2b/3 which can have monotherapy + 2 A2-73 doses per day which may give better results.
That may be the reason the next trial is not started -use this data to refine the protocol before starting the trial
Speculation: Dosage tolerance and efficacy higher and greater in Mono-therapy..
The pharmacokinetic response to MTD is probably different in MonoTherapy vs Combination. Less does more..
Wonder also if MTD in mono group was higher? Or the same .. or maybe even less?
My medical knowledge is obviously limited( a big ditto to all my other knowledges ). But if Aricept competed for Sigma 1 we may need less A2-73 to be more effective, thus making cheaper to use and even safer... Towards my lack of knowledge, I read that the dosage of A2-73 was tremendously less than other medications ? Is this reasonable? Aricept is 25 Mg (again consider my brain capacity) seems like it is about the same..
News 
Market Data 
Discover 
